Novartis' ianalumab plus eltrombopag significantly extended treatment response and improved platelet counts in a Phase 3 ...

Ianalumab added to eltrombopag significantly prolonged the time to treatment failure (TTF) in adults with primary immune thrombocytopenia (ITP), a B cell-driven autoimmune disease, according to phase ...

The pharma company said the drug combined with eltrombopag demonstrated a significant improvement in time to treatment ...

Novartis (NVS) announced positive top-line results from VAYHIT2, a Phase III trial evaluating ianalumab plus eltrombopag in patients with primary ...

SAN DIEGO — Eltrombopag conferred a higher rate of durable platelet response in the absence of rescue treatments than standard first-line treatments for children with newly diagnosed immune ...

While eltrombopag, a small-molecule non-peptide thrombopoietin receptor agonist, has been approved for children with chronic ITP, its efficacy in newly diagnosed pediatric ITP is unknown.

Eltrombopag (Promacta) is an oral thrombopoietin mimetic that binds to c-MPL, promoting megakaryopoiesis and release of platelets from mature megakaryocytes. 12 Eltrombopag increases platelet ...

Eltrombopag (SB-497115, GlaxoSmithKline) is a new, small-molecule, nonpeptide, oral platelet growth factor that acts as a thrombopoietin-receptor agonist.

This trial suggests that eltrombopag, especially at a daily dose of 75 mg, is effective in raising platelet counts in cirrhotic HCV-positive patients, and it seems to be safe.

However, eltrombopag and romiplostim should never be considered as front-line treatment of the disease, George said. “These drugs are very expensive and they are maintenance therapies,” he said.